DiaMedica Therapeutics Inc. has reported its financial results for the first quarter of 2025. The company experienced a net loss of $7.7 million for the quarter ended March 31, 2025, compared to a net loss of $5.2 million for the same period in 2024. This translates to a loss per share of $0.18, an increase from the $0.14 loss per share reported in the previous year. The increase in net loss is attributed to higher research and development expenses, which amounted to $5.7 million, up from $3.7 million in the first quarter of 2024. This rise in expenses was primarily due to the continuation and global expansion of the ReMEDy2 clinical trial and increased manufacturing development activities. General and administrative expenses also saw an increase, totaling $2.5 million compared to $2.1 million in the same period last year, driven largely by additional non-cash share-based compensation. As of March 31, 2025, DiaMedica's cash, cash equivalents, and short-term investments stood at $37.3 million, down from $44.1 million as of December 31, 2024. The company anticipates that its current cash position will support planned clinical studies and corporate operations into the third quarter of 2026. In terms of operational updates, DiaMedica is progressing with its Acute Ischemic Stroke Phase 2/3 program as planned and expects to report topline DM199 Preeclampsia Phase 2 Part 1A proof of concept results in the near term, with Phase 2 Part 1B expected to initiate in the third quarter of 2025. Additionally, a Key Opinion Leader event is scheduled for May 28, 2025, to discuss the disease of preeclampsia and the ongoing DM199 Phase 2 study design.